Speakers

Expand/Collapse

Ania Wronski
Director, Market Development
Mission Bio

Day Two

Thursday November 18, 2021

11:35 am | Singling Out the Cuts: Single-Cell Multi-Modal Analysis for CRISPR- Edited Cells

Max Sellman
Product Manager - Gene Editing
Aldevron

Day One

Wednesday November 17, 2021

11:50 am | CRISPR-Associated Nucleases for Gene Editing: Tools to Support Discovery and Therapeutic Programs

John Murphy
Chief Scientific Officer
Arbor Biotechnologies

Day One

Wednesday November 17, 2021

4:30 pm | Arbor Discovery’s Novel Process and Protein Engineering Approach

Roy Ziblat
Scientific Manager
Arbor Biotechnologies

Day Two

Thursday November 18, 2021

12:45 pm | Function & Discoveries of the Arbor Discovery Line Using Type V Systems

Luisa Loiacono
Senior Research Scientist
AstraZeneca

Day One

Wednesday November 17, 2021

9:00 am | Panel Discussion: Driving CRISPR Technology to the Clinic

Day Two

Thursday November 18, 2021

9:15 am | Safety of CRISPR-Cas9 in Therapy: A Call to Action

Joseph Miano
J. Harold Harrison, MD, Distinguished University Chair in Vascular Biology
Augusta University

Jacob Layer
Senior Scientist, Group Leader
eGenesisbio

Day Two

Thursday November 18, 2021

12:15 pm | Innovating Xenotransplantation with Genome Editing

Pankaj Mandal
Senior Staff Fellow, Office of Tissues & Advanced Therapies, Division of Cellular & Gene Therapies
FDA/CBER

Day One

Wednesday November 17, 2021

8:30 am | FDA’s Regulatory Approach to CRISPR Technology

Kalina Paunovska
Postdoctoral Scholars
Georgia Institute of Technology, Dahlman Lab

Day One

Wednesday November 17, 2021

2:00 pm | CRISPR Delivery via the Use of Lipid Nanoparticles Delivery

Danilo Maddalo
Senior Scientist
Genentech

Day One

Wednesday November 17, 2021

9:00 am | Panel Discussion: Driving CRISPR Technology to the Clinic

Day Two

Thursday November 18, 2021

2:15 pm | SEMMs: Somatically Engineered Mouse Models, A New Tool for Translational Preclinical Research

Danny Dever
Head of Discovery Research
GraphiteBio

Day One

Wednesday November 17, 2021

9:00 am | Panel Discussion: Driving CRISPR Technology to the Clinic

Day Two

Thursday November 18, 2021

3:15 pm | Investigate the Therapeutic Potential of CRISPR Technology in Treating Sickle Cell Disease

Ben Kleinstiver
Assistant Professor
Mass General Hospital & Harvard Medical School

Day One

Wednesday November 17, 2021

4:00 pm | Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties

Sean Burns
Vice President, Disease Biology
Intellia Therapeutics

Day Two

Thursday November 18, 2021

2:45 pm | Development of Systemic CRISPR-based Therapeutics

Gregory Cost
Senior Director of Biology
Metagenomi

Day One

Wednesday November 17, 2021

3:30 pm | Novel CRISPR-Associated Gene-Editing Systems Discovered in Metagenomic Samples Enable Efficient & Specific Genome Engineering For Cell Therapy Development

Brett Staahl
Vice President Platform, Co- Founder
Scribe Therapeutics

Day One

Wednesday November 17, 2021

10:50 am | Solving the Challenges of Editing & In Vivo Delivery

Niren Murthy
Professor, Bioengineering
University of California at Berkeley

Day One

Wednesday November 17, 2021

1:30 pm | New Delivery Vehicles for Gene Editing Enzymes

Andrew Anzalone
Head of Prime Editing Platforms
Prime Medicine

Day Two

Thursday November 18, 2021

10:15 am | Exploring the Potential of Prime Editing

Jyun-Liang “Aaron” Lin
Scientist II
Metagenomi

Day Two

Thursday November 18, 2021

9:45 am | Compact Adenine Base Editor with Novel Microbial Components

Rafi Emmanuel
Senior Vice President, R&D
Emendo Biotherapeutics

Day Two

Thursday November 18, 2021

11:45 am | EMD-101, A Potential Autologous HSC-Based Therapy for ELANE-Related Severe Congenital Neutropenia

Clarence Mills
Research Scientist
Horizon Discovery

Day One

Wednesday November 17, 2021

9:30 am | CRISPR Without the Cut: Introducing Horizon’s CRISPRi Portfolio

Christopher Brown
Director, Discovery
Metagenomi

Day One

Wednesday November 17, 2021

11:20 am | Expanding the Genome Editing Toolbox with Metagenomics

Tomomi Aida
Research Scientist, Feng Lab
Massachusetts Institute of Technology

Channabasavaiah Gurumurthy
Director, Mouse Genome Engineering Core Facility
University of Nebraska Medical Center

Melissa Lokugamage
Venture Capitalist
Alloy Therapeutics